Articles related to RARE CONDITIONS & DISEASES

A clinical picture of the spontaneous pneumothorax, which is considered spontaneous if there is no apparent precipitating cause and can be easily missed on a chest radiograph unless there is a strong index of clinical suspicion. This article discusses risk factors, diagnosis, and treatment for the condition.

Dr. Lucinda A. Harris, an associate professor of medicine at the Mayo Clinic Alix School of Medicine in Scottsdale, AZ, offers her evidence-based approach to diagnosing and treating these five rare GI diseases: Non-celiac gluten sensitivity Eosinophilic esophagitis Postural orthostatic tachycardia syndrome (POTS) Ehlers-Danlos syndrome Mast cell activation syndrome

Burkholderia pseudomallei bacteria showed up in four patients in Georgia, Kansas, Minnesota, and Texas in 2021, despite the bacterium typically associated with travel to tropical and subtropical areas like Thailand and Malaysia. The case was cracked when researchers found an essential oil spray that contained B. pseudomallei in the home of a 4-year-old boy who died from complications of the melioidosis outbreak.

Giant cell arteritis (GCA) is one of the most dangerous rheumatologic conditions, and mortality rates among patients with the condition in Canada’s Ontario province has researchers very concerned without any explanation for the recent increases in mortality they documented. MedPage Today shares the report from Arthritis Care & Research.

The 28-year-old Canadian pop star recently put the condition into the limelight after showing his face to his millions of Instagram followers. Ramsay Hunt Syndrome is caused by the varicella-zoster virus – the virus that causes chickenpox – but here’s more on the condition that plagues 5 in 100,000 people every year.

This report includes 3-year follow-up of the pivotal ZUMA-2 study of KTE-X19 in relapsed/refractory MCL. At a median follow-up of 35.6 months, the objective response rate among all 68 treated patients was 91%, with 68% complete responses. Medians for duration of response, progression-free survival, and overall survival were 28.2 months, 25.8 months, and 46.6 months, respectively. “These data, representing the longest follow-up of CAR T-cell therapy in patients with MCL to date, suggest that KTE-X19 induced durable long-term responses with manageable safety in patients with relapsed/refractory MCL and may also benefit those with high-risk characteristics.”